Pitfalls in genetic testing: the story of missed SCN1A mutations


1Neurogenetics group, Department of Molecular Genetics, VIB, Antwerp, Belgium
2Laboratory of Neurogenetics, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium
3Sorbonne université, UPMC université Paris 06, 91-105, boulevard de l’Hôpital, Paris 75013, France
4ICM, CNRS UMR 7225, Inserm U 1127, 47/83, boulevard de l’Hôpital, Paris 75013, France
5Centre de reference épilepsies rares, Epilepsy unit, AP-HP Groupe hospitalier Pitié-Salpêtrière, Paris 75013, France
6Department of Neuroepidemiology, University Medical Center Schleswig-Holstein, Kiel, Germany
7Division of Genetic Medicine, Department of Pediatrics, University of Washington, Seattle, Washington 98195
8Folkhålsan Institute of Genetics, Helsinki, Finland
9Medical and Clinical Genetics, University of Helsinki, Helsinki, Finland
10Helsinki University Hospital, Helsinki, Finland
11Department of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands
12Department of Molecular Biology and Genetics, Bogazici University, Istanbul, Turkey
13Département de génétique, AP-HP, hôpital Pitié-Salpêtrière, 47/83, boulevard de l’Hôpital, Paris 75013, France
14Department of Pediatric Neurology, Helsinki University Hospital, Helsinki, Finland
15Laboratory of Genetics, E.O. Ospedali Galliera, Genova, Italy
16Neurology Laboratory and Epilepsy Unit, Department of Neurology, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain
17IS-Fundación Jiménez Díaz and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
18Psychiatric and Neurodevelopmental Genetics Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114
19Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142
20Wellcome Trust Sanger Institute, Hinxton, United Kingdom
21Pediatrie Neurology and Neurogenetics Unit and Laboratories, A. Meyer Children’s Hospital-University of Florence, Florence, Italy
22Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland
23Department of Clinical and Experimental Epilepsy, NIHR University College London Hospitals Biomedical Research Centre, UCL Institute of Neurology, London, United Kingdom
24The Epilepsy Society, Chalfont-St-Peter, Bucks, United Kingdom
25Department of Neurology, Danish Epilepsy Centre, Dianalund, Denmark
26Institute for Regional Health research, University of Southern Denmark, Odense, Denmark
27Research Programs Unit, Molecular Neurogenetics, University of Helsinki, Helsinki, Finland
28Institute of Human Genetics, University of Leipzig, Leipzig, Germany
29Epilepsy Research Centre, Department of Medicine, University of Melbourne, Austin Health, Melbourne, Australia
30Pediatric Neurology and Muscular Diseases Unit, Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, and Maternal and Child Health, University of Genoa ‘G. Gaslini’ Institute, Genova, Italy
31Laboratory of Neurogenetics, Department of Neurosciences, Giannina Gaslini Institute, Genova, Italy
32Department of Paediatrics, University of Melbourne and Royal Children’s Hospital, Parkville, Victoria 3052, Australia
33Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria 3084, Australia
34Division of Neurology, Antwerp University Hospital, Antwerp, Belgium
35Division of Neurology, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
36GENOMED, Center for Medical Genetics, University of Antwerp, Antwerp, Belgium

© 2016 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Keywords
Dravet syndrome, epilepsy, genetic screening, next-generation sequencing, Sanger sequencing.

Correspondence
Arvid Suls, Center for Medical Genetics, University of Antwerp, Campus Drie Eiken, Prins Boudewijnlaan 43, D PrBG.234, 2650 Edegem, Belgium. Tel: +32 3 275 97 69; Fax: +32 3 275 97 23; E-mail: arvid.suls@uantwerpen.be

Funding information
This study was funded by the following sources: Assistance Publique des Hôpitaux de Paris (AP-HP), Dravet Syndrome UK, the Katy Baggott Foundation, the Epilepsy Society, the International Coordination Action (ICA, grant G0E8614N), and EpIPGX (European Union 7th Framework Programme Grant 279062). This work was partly undertaken at UCLH/UCL, which received a proportion of funding from the UK Department of Health’s NIHR Biomedical Research Centres funding scheme. This work was supported by Folkhälsoan Research Foundation (A-KA, A-EL). Within the Eurocores program of the European Science Foundation P.D.J. (G.A.136.11.N and FWO/ESF-ECRP) and I.H. (HE5415/3-1) received financial support within the EuroEPINOMICS-RES network. H.C. is granted by the TUBITAK project no 110S518. S.v.S, H.M., U.S. and I.H. received funding from the medical faculty of Kiel University, Germany. T.D. is a PhD fellow of the Institute of Science and Technology (IWT). A.S. was a postdoctoral fellow of the Fund for Scientific Research Flanders (FWO). S.W. is supported by French program “Investissements d’avenir” (ANR-10-IAIHU-06).

Received: 25 November 2015; Revised: 23 February 2016; Accepted: 25 February 2016

Molecular Genetics & Genomic Medicine
doi: 10.1002/mgg3.217

Introduction
When it comes to genetic screenings, Sanger sequencing has long been considered the gold standard and is still widely performed. However, next-generation sequencing (NGS) is becoming steadily implemented nowadays, both in research and in clinical diagnostic settings. Whereas Sanger sequencing targets only one gene at a time, making it a very time and cost-consuming method, NGS technologies can analyze a set of genes, an exome, or even a genome in a single sequencing run. This enormous advantage has led to the widespread implementation of different NGS platforms in genetic centers (Sisodiya 2015). It is well-known that no single mutation detection technique is perfect in identifying all mutations. Therefore, we wondered to what extent inconsistencies between Sanger sequencing and NGS affect the molecular diagnosis of patients. Since mutations in SCN1A, the major gene implicated in epilepsy, are found in the majority of Dravet syndrome (DS) patients, we focused on missed SCN1A mutations.

Abstract
Background
Sanger sequencing, still the standard technique for genetic testing in most diagnostic laboratories and until recently widely used in research, is gradually being complemented by next-generation sequencing (NGS). No single mutation detection technique is however perfect in identifying all mutations. Therefore, we wondered to what extent inconsistencies between Sanger sequencing and NGS affect the molecular diagnosis of patients. Since mutations in SCN1A, the major gene implicated in epilepsy, are found in the majority of Dravet syndrome (DS) patients, we focused on missed SCN1A mutations.

Methods
We sent out a survey to 16 genetic centers performing SCN1A testing.

Results
We collected data on 28 mutations initially missed using Sanger sequencing. All patients were falsely reported as SCN1A mutation-negative, both due to technical limitations and human errors.

Conclusion
We illustrate the pitfalls of Sanger sequencing and most importantly provide evidence that SCN1A mutations are an even more frequent cause of DS than already anticipated.
on Sanger sequencing turn out to be false negative when subsequently analyzed by NGS. To answer this question, we focused our study on screenings of the SCN1A gene (OMIM: #152389) in Dravet syndrome (DS), one of the genetically most homogeneous epileptic syndromes.

DS is among the best defined and most extensively studied entities within the epileptic encephalopathies. Clinically, the disease is characterized by a seizure onset in the first year of life, usually around six months. Seizures at onset are fever sensitive, and mostly consist of generalized or unilateral, often prolonged, clonic, and tonic–clonic seizures. As the disease progresses, afebrile seizures co-occur, and other seizure types such as myoclonic seizures, atypical absences, and focal seizures become more prominent (Dravet 2011). Seizures usually are resistant to currently available antiepileptic drugs. The development of patients with DS is initially normal. During the second year of life however, developmental delay and other neurological defects become apparent (Brunklaus et al. 2012).

The most important gene implicated in DS is SCN1A, encoding the alpha subunit of the neuronal voltage-gated sodium channel Na+1.1. About 70% to 80% of DS patients are shown to carry an SCN1A mutation of which 90% occur de novo (Claes et al. 2001; Depienne et al. 2009). Single nucleotide substitutions, small indels, and even whole gene deletions have been reported with at least 1257 different mutations described to date (Suls et al. 2006; Zuberi et al. 2011; Meng et al. 2015). These mutations occur randomly throughout the gene, without the presence of mutational hotspots. Recently, mutations in several other genes including PCDH19, GABRG2, CHD2, and HCN1 have been associated with a DS phenotype. However, each of these genes only has a small contribution.

SCN1A mutations can also be found in a few other epileptic syndromes that show some clinical similarities to DS, such as myoclonic atonic epilepsy (MAE) and genetic epilepsy with febrile seizures plus (GEFS+). The mutation yield in these syndromes is however much lower, ranging from a few percent up to 10% (Hirose et al. 2013).

Despite the significant contribution of genetic alterations in SCN1A to DS, a subset of patients remain without a genetic diagnosis after testing of SCN1A with Sanger sequencing. These patients may harbor mutations in one of the “minor” Dravet genes but could also represent SCN1A false-negative cases that are carrying an SCN1A mutation missed by Sanger sequencing. Within our EuroEPINOMICS-RES consortium, we performed whole-exome sequencing (WES) on 31 DS trios (patient and healthy parents; cohort previously described (Syrbe et al. 2015)) identifying SCN1A mutations in eight patients considered SCN1A mutation-negative upon Sanger screening (unpublished data). This observation shows the limitations of Sanger sequencing, but most importantly indicates that SCN1A mutations are an even more frequent cause of DS than is generally accepted.

After our prospective EuroEPINOMICS-RES consortium study we conducted an additional retrospective study to collect additional information on missed SCN1A mutations and explored why all these mutations were originally missed.

Materials and Methods

The study was approved by the local ethics committees of participating centers. The protocol and procedures employed were reviewed and approved by the appropriate institutional review committee. Informed consent was obtained for the patients described in this study. The following procedures were in accordance with the ethical standards of the responsible committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.

We sent out a survey to 16 genetic centers performing SCN1A screening on a diagnostic and/or research basis, to collect information on SCN1A mutations (RefSeq NM_001165963.1) that were searched for by Sanger sequencing, but were only subsequently identified by NGS. This study was broader than DS and included all phenotypes related to SCN1A. In order to compare the results of these genetic tests, we decided to only analyze detection errors of point mutations or small insertions or deletions. Partial/whole gene deletions and occasionally duplications of SCN1A are also a well-documented cause of DS. These structural alterations can be missed by Sanger sequencing and may undoubtedly contribute to the group of SCN1A false-negative cases. This was confirmed in the EuroEPINOMICS-RES cohort where testing with array-CGH detected two deletions in the remaining 23 SCN1A-negative patients (unpublished data). In the retrospective study, we did not include copy number variants since calling these variants from NGS data is still challenging and clear comparisons between the results of the techniques can thus not be made. With the questionnaire, we specifically asked for information on the sequencing techniques, the reasons for missing the mutation, the setting (diagnostic vs. research), and the date of the screening. All mutations have been submitted to the SCN1A database (http://www.gzneurosci.com/scn1adatabase/index.php).

Results

We received a response from 16 different genetic centers, of which 13 had one or more patients to include. In the retrospective study, we collected information on 20 additional patients harboring an SCN1A mutation that was
missed by Sanger sequencing but confirmed by NGS and one patient in whom an SCN1A mutation was detected by Sanger sequencing that was missed in a WES study looking for modifiers (Table 1). Eighteen patients were diagnosed with DS, two other patients presented a phenotypically related epilepsy syndrome (GEFS+, MAE) and one patient had an epileptic encephalopathy without further phenotypical information (Table 1). Seven of the patients have previously been reported (patient 2, 16, 17, 18, 19, 20, 29) (Table 1).

When comparing the technologies, 28 mutations were detected using NGS after prior screening with Sanger sequencing was reported to be negative. One mutation was initially found by Sanger sequencing but subsequent WES (aiming to investigate additional genetic modifiers) failed to identify the mutation. Reasons for missing these mutations can be classified into three categories (Table 2): mutations were missed due to (1) human errors, (2) technical problems of the screening technique, and (3) unknown reasons.

The most frequent reason for reporting false-negative results were human errors (19/29; 66%). In retrospect, for nine patients, the mutation was present in the Sanger traces, but was simply overlooked by the person performing the initial analysis. Problems with primer design led to false-negative results in four patients. The medical report of one patient erroneously stated that he was sequenced although he never was; a sample switch occurred for one patient; one patient was assigned the wrong sequencing data; for one the Sanger sequencing results were of bad quality so the sequencing should have been repeated; and for another patient, the mutation was positioned eight base pairs into the intron and was therefore considered not significant and thus not mentioned in the diagnostic report. Finally, one patient had an intronic deletion leading to misalignment of the reads and consequently uninterpretable data.

In three patients (10%), technical problems led to missing the mutations. One mutation was not identified in the Sanger traces due to the use of an excessively high primer annealing temperature, but was detected by WES and confirmed in a second Sanger sequencing run at a lower temperature. For one patient, the peak of the mutation in the electropherogram was too low to be called as a variant by the analysis software. A first WES run on this sample suggested mosaicism (49 reference reads vs. 18 variant reads), and this was confirmed by a second WES run (169 reference reads vs. 81 variant reads). The mutation detected by Sanger but subsequently missed by WES was an A>T substitution lying in a stretch of adenine nucleotides, creating a long homopolymer knowing to cause problems in variant calling (both false-positive and false-negative calls) using NGS sequencing. For the remaining seven patients, we could not trace the original sequencing reports and were thus unable to identify the exact reason for mutation detection failure.

Discussion

When comparing sequencing techniques, our data show that Sanger sequencing resulted in 28 false-negative results while NGS missed one mutation. First of all, it should be noted that these numbers probably give an incorrect impression of the reliability of the different techniques, since our retrospective analysis creates an ascertainment bias toward patients initially screened by Sanger sequencing. Although NGS is the logical next step when Sanger sequencing is negative, few patients will undergo Sanger sequencing after a negative NGS screening, unless there is evidence of low coverage of a particular gene or a particularly convincing phenotype.

Both techniques clearly have their own technical limitations, as illustrated in this study. NGS is known to be superior to Sanger sequencing for the detection of low levels of mutant allele, as seen in mosaicism. A probable mosaic mutation was indeed first missed by Sanger sequencing, but subsequently detected by WES in one patient in this study (patient 21). The importance of germline and somatic mosaicism is well established in a broad range of diseases, including DS (Vadlamudi et al. 2010), and highlights the usefulness of high coverage NGS techniques for mosaic mutation detection. A major weakness of NGS on the other hand is the sequencing of stretches of the same nucleotide, which can lead to homopolymer-associated insertion and deletion errors due to the nonlinear light response generated by the nucleotide stretches (patient 22). Another disadvantage of NGS is the use of relatively short reads, although read lengths are increasing steadily with advancing NGS techniques. Short reads can lead to problems with mapping quality, especially in repeat regions, which in turn can result in misalignments and misinterpretation of the data (Stranneheim and Lundeborg 2012).

Our study further showed that the majority (19/29) of mutations were missed due to human errors, which in most cases could have been prevented by applying rigorous quality controls. Sample handling and allocation remain error-prone steps independent of the sequencing technology. In this context, the use of a well-functioning laboratory information management system (LIMS) is crucial. Keeping track of all the processes and logging every detail may seem very labor intensive, but might eventually save the costs of a potential redundant NGS experiment. In recent years, strict quality control procedures and criteria, including the use of LIMS, have been developed for diagnostic genetic laboratories, and are expected to result in a reduction of human errors.
The Story of Missed SCN1A Mutations

Also the analysis/interpretation process is prone to errors that are more difficult to eradicate. Errors resulting from visual inspection of Sanger traces can be circumvented by using automated variant calling. Errors related to primer design can be overcome by a more careful control of parameters used in software for primer design. Recent years have also brought us more sophisticated in silico variant annotation and prediction tools that are greatly aiding in our interpretation of variants, as illustrated for the splice variant in patient 18. Our data show that most mutations were missed during the early implementation of SCN1A mutation testing in clinical practice. Nevertheless, even during the last two years false-negative results were generated in a highly regulated diagnostic setting, which shows that there is still room for improvement of quality control (Table 1).
Identifying SCN1A mutations in patients supposed to be SCN1A-negative is not a unique observation of our study but has been described previously. Carvill et al. reported three mutations in 13 patients with DS in whom a previous SCN1A screening turned out negative (Carvill et al. 2014). Lemke et al. described two mutations in a cohort of 33 patients with diverse epilepsy phenotypes (Lemke et al. 2012), Bayat et al. mentioned two patients with DS who initially tested negative upon SCN1A screening (Bayat et al. 2015) and Gaily et al. reported one such patient (Gaily et al. 2013). Finding a mutation in pre-screened and so-called mutation-negative patients is also not limited to SCN1A, nor the epilepsy field. For example, Klein and colleagues described five kindreds with inherited polyneuropathy in whom WES identified known pathogenic mutations that were initially overlooked by Sanger sequencing, showing this phenomenon to be a general concern for genetic diagnostics (Klein et al. 2014).

In total, we collected 29 SCN1A mutations in DS patients erroneously reported as mutation-negative. This illustrates that the frequency of SCN1A mutations in DS is still underestimated and higher than the reported 80%. The identification of an SCN1A mutation in 32% (10/31) of DS patients from our “SCN1A-negative” EuroEPI-NOMICS-RES consortium study clearly shows that DS is even more genetically homogenous than previously anticipated. That 13 of the 16 participating centers contributed false-negative cases indicates that missing SCN1A mutations occurs regularly. However, the exact frequency could not be determined as in the prospective EuroEPI-

Table 2. Overview of the different reasons that SCN1A mutations were missed in a genetic screening.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Negative screening</th>
<th>Positive screening</th>
<th>Reason that the mutation was missed</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Sanger</td>
<td>Sanger</td>
<td>Missed by the person performing the mutation analysis (visual inspection of Sanger traces)</td>
</tr>
<tr>
<td>2</td>
<td>Sanger</td>
<td>Sanger</td>
<td>Missed by the person performing the mutation analysis (visual inspection of Sanger traces)</td>
</tr>
<tr>
<td>3</td>
<td>Sanger</td>
<td>Sanger</td>
<td>Missed by the person performing the mutation analysis (visual inspection of Sanger traces)</td>
</tr>
<tr>
<td>4</td>
<td>Sanger</td>
<td>Sanger</td>
<td>Missed by the person performing the mutation analysis (visual inspection of Sanger traces)</td>
</tr>
<tr>
<td>5</td>
<td>Sanger</td>
<td>Sanger</td>
<td>Missed by the person performing the mutation analysis (visual inspection of Sanger traces)</td>
</tr>
<tr>
<td>6</td>
<td>Sanger</td>
<td>Sanger</td>
<td>Missed by the person performing the mutation analysis (visual inspection of Sanger traces)</td>
</tr>
<tr>
<td>7</td>
<td>Sanger</td>
<td>Sanger</td>
<td>Missed by the person performing the mutation analysis (visual inspection of Sanger traces)</td>
</tr>
<tr>
<td>8</td>
<td>Sanger</td>
<td>Sanger</td>
<td>Missed by the person performing the mutation analysis (visual inspection of Sanger traces)</td>
</tr>
<tr>
<td>9</td>
<td>Sanger</td>
<td>Sanger</td>
<td>Missed by the person performing the mutation analysis (visual inspection of Sanger traces)</td>
</tr>
<tr>
<td>10</td>
<td>Sanger</td>
<td>Sanger</td>
<td>Missed by the person performing the mutation analysis (visual inspection of Sanger traces)</td>
</tr>
<tr>
<td>11</td>
<td>Sanger</td>
<td>Sanger</td>
<td>Error in the primer design: The mutation was located in the primer binding site</td>
</tr>
<tr>
<td>12</td>
<td>Sanger</td>
<td>Sanger</td>
<td>Error in the primer design: A polymorphism in the primer led to mono-allelic amplification</td>
</tr>
<tr>
<td>13</td>
<td>Sanger</td>
<td>Sanger</td>
<td>Error in the primer design: A polymorphism in the primer led to mono-allelic amplification</td>
</tr>
<tr>
<td>14</td>
<td>Sanger</td>
<td>Sanger</td>
<td>Error in the primer design: The primer did not cover the whole amplicon (only one direction was sequenced)</td>
</tr>
<tr>
<td>15</td>
<td>Sanger</td>
<td>Sanger</td>
<td>The patient turned out not to be sequenced</td>
</tr>
<tr>
<td>16</td>
<td>Sanger</td>
<td>Sanger</td>
<td>Possible sample swap outside the lab</td>
</tr>
<tr>
<td>17</td>
<td>Sanger</td>
<td>Sanger</td>
<td>Wrong sequencing data assigned to the patient</td>
</tr>
<tr>
<td>18</td>
<td>Sanger</td>
<td>Sanger</td>
<td>The traces were of bad quality so the Sanger should have been redone</td>
</tr>
<tr>
<td>19</td>
<td>Sanger</td>
<td>Sanger</td>
<td>Not reported in the diagnostic report as the mutation is located eight base pairs in the intron</td>
</tr>
<tr>
<td>20</td>
<td>Sanger</td>
<td>Sanger</td>
<td>An adjacent intronic polymorphic deletion led to misalignment of the alleles and uninterpretable data</td>
</tr>
<tr>
<td>21</td>
<td>Sanger</td>
<td>Sanger</td>
<td>The annealing temperature of the primers was too high for the polymerase</td>
</tr>
<tr>
<td>22</td>
<td>Sanger</td>
<td>Sanger</td>
<td>The mutated peak was too low</td>
</tr>
<tr>
<td>23</td>
<td>Sanger</td>
<td>Sanger</td>
<td>The mutation is located in a homopolymer stretch</td>
</tr>
<tr>
<td>24</td>
<td>Sanger</td>
<td>Sanger</td>
<td>Unable to retrieve the Sanger traces</td>
</tr>
<tr>
<td>25</td>
<td>Sanger</td>
<td>Sanger</td>
<td>Unable to retrieve the Sanger traces</td>
</tr>
<tr>
<td>26</td>
<td>Sanger</td>
<td>Sanger</td>
<td>Unable to retrieve the Sanger traces</td>
</tr>
<tr>
<td>27</td>
<td>Sanger</td>
<td>Sanger</td>
<td>Unable to retrieve the Sanger traces</td>
</tr>
<tr>
<td>28</td>
<td>Sanger</td>
<td>Sanger</td>
<td>Unable to retrieve the Sanger traces</td>
</tr>
</tbody>
</table>

NGS: next-generation sequencing; WES: whole-exome sequencing. Seven patients have previously been reported.

1LeM et al., 2012.
2Bayat et al., 2015.
3Carvill et al., 2014.
4Gaily et al., 2013.
NOMICS-RES study. Given the variability in data storage procedures of the different genetic centers involved in this study, we were unable to retrieve information on the total number of SCN1A-negative patients that underwent a genetic screening with a second technology.

Given the high genetic homogeneity of DS, first-line testing for DS should be the search for an SCN1A mutation. Whether this is performed using Sanger sequencing or NGS (e.g., a gene panel with a high coverage of SCN1A) seems to be of lesser importance as no technique is perfect in identifying all the mutations. In case of a negative SCN1A test in a patient with a convincing clinical suspicion of DS, we recommend clinicians to discuss the need to use a second genetic technique and analyze SCN1A in depth to be absolutely sure that no mutation is present. It should however be noted that despite the clear genotype–phenotype correlation between SCN1A mutations and DS, mutations in several other genes have also been associated with a DS phenotype (Depienne et al. 2009; Carvill et al. 2014; Nava et al. 2014). Additionally, aside from these “missed” coding mutations, we can expect that mutations in non-coding regulatory regions of SCN1A and possibly also epigenetic factors affecting the gene might play a role in the pathogenesis of DS. A negative SCN1A screening should therefore not be considered as an exclusion factor for DS.

Finding a mutation and thus providing a clear etiological diagnosis has major implications for the patient and his/her family comprising not only issues related to prognosis and family planning but also interventions toward a more tailored treatment.

Acknowledgments

We thank the families and patients for their participation in this study. This study was funded by the following sources: Assistance Publique des Hôpitaux de Paris (AP-HP), Dravet Syndrome UK, the Katy Baggott Foundation, the Epilepsy Society, the International Coordination Action (ICA, grant G0E8614N), and EpiPGX (European Union 7th Framework Programme Grant 279062). This work was partly undertaken at UCLH/UCL, which received a proportion of funding from the UK Department of Health’s NIHR Biomedical Research Centres funding scheme. This work was supported by Folkhalsan Research Foundation (A-KA, A-EL). Within the Eurocores program of the European Science Foundation P.D.J. (G.A.136.11.N and FWO/ESF-ECRP) and I.H. (HE5415/3-1) received financial support within the EuroEPINOMICS-RES network. H.C. is granted by the TUBITAK project no 110S518. S.v.S., H.M., U.S. and I.H. received funding from the medical faculty of Kiel University, Germany. T.D. is a PhD fellow of the Institute of Science and Technology (IWT). A.S. was a postdoctoral fellow of the Fund for Scientific Research Flanders (FWO). S.W. is supported by French program “Investissements d’avenir” (ANR-10-IAIHU-06).

Conflict of Interest

None declared.

References


